73799-63-0

Usage

Uses

Used in Pain Management:
Cyclazocine was once used as a strong analgesic medication for the management of severe pain. It acted on the κ-opioid receptors to provide pain relief.
Used in Antitussive Medication:
In the past, cyclazocine was also utilized as an antitussive agent to help suppress coughing.
Used in Addiction Treatment:
Cyclazocine has been investigated for its potential as a treatment for addiction to other opioids. It can produce similar effects to morphine but with less potential for respiratory depression and physical dependence, although its use in this context remains limited.
Used in Neuroprotection and Antidepressant Research:
Cyclazocine has been studied for its potential neuroprotective and antidepressant effects, but further research is needed to fully understand its pharmacological properties and potential therapeutic uses in these areas.

Upstream product

• 5617-74-3 3-oxabicyclo[3.1.0]hexane-2,4-dione 
• 100-46-9 benzylamine 
• 5617-74-3 cis-1,2-cyclopropanedicarboxylic acid anhydride 
• 1631-26-1 1-benzyl-1H-pyrrole-2,5-dione 
• 200620-00-4 C₁₂H₁₁N₃O₂ 
• 5617-69-6 3-aza-bicyclo[3.1.0]hexane-2,4-dione 
• 710-43-0 cis-cyclopropane-1,2-dicarboxylic acid diethyl ester 
• 696-74-2 cis-1,2-cyclopropanedicarboxylic acid 

Downstream Products

• 1431772-73-4 3-(8-(6-(3-aza-bicyclo[3.1.0]hexan-3-yl)pyridin-2-ylamino)imidazo[1,2-b]pyridazin-6-yl)benzoic acid 
• 1431773-81-7 methyl 3-(8-(6-(3-aza-bicyclo[3.1.0]hexan-3-yl)pyridin-2-ylamino)imidazo[1,2-b]pyridazin-6-yl)benzoate 
• 659736-81-9 3-benzyl-2-methyl-3-azabicyclo[3.1.0]hexane 
• 285-59-6 3-azabicyclo [3.1.0]hexane 
• 659736-80-8 3-benzyl-4-hydroxy-4-methyl-3-azabicyclo[3.1.0]hexane-2-one 
• 70110-45-1 3-benzyl-3-aza-bicyclo[3.1.0]hexane 
• 1420294-81-0 3-benzyl-3-azabicyclo[3.1.0]hexane hydrochloride 

Relevant academic research and scientific papers

INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL

The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential Al ion channel (TRPA1).

Prodrugs Of Bicyclic Substituted Pyrimidine Type PDE-5 Inhibitors

Provided are prodrugs of a bicyclic substituted pyrimidine type PDE-5 inhibitors, pharmaceutically acceptable salts or stereoisomers thereof. Also provided are methods for preparing these prodrug compounds, pharmaceutical preparations, and pharmaceutical compositions, as well as a use of these compounds, pharmaceutical preparations and pharmaceutical compositions in the manufacture of medicaments for treatment and/or prophylaxis of sexual dysfunction and lower urinary tract symptoms.

INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL

The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential Al ion channel (TRPA1).

9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUND

The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7, R8, R9a, R9b, R10, R11, R12, R13a and R13b are each independently as defined in the description.

9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS

The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7, R8, R9a, R9b, R10, R11, R12, R13a and R13b are each independently as defined in the description.

IMIDAZOPYRIDAZINE COMPOUNDS

The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

IMIDAZOPYRIDAZINE COMPOUNDS

The present invention relates to the use of novel compounds of formula (I): wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Solid-state photochemistry of crystalline pyrazolines: Reliable generation and reactivity control of 1,3-biradicals and their potential for the green chemistry synthesis of substituted cyclopropanes

To expand on the limited number of examples that exist in the literature for the solid-state photodenitrogenation of azoalkanes, a series of crystalline 7-alkyl-2,3,7-triazabicyclo[3.3.0]oct-2-ene-6,8-diones with varying 4,4-substituents were prepared. Th

Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors

The synthesis and structure-activity relationships of novel dipeptidyl peptidase IV inhibitors replacing the classical cyanopyrrolidine P1 group with other small nitrogen heterocycles are described. A unique potency enhancement was achieved with β-branched natural and unnatural amino acids, particularly adamantylglycines, linked to a (2S,3R)-2,3-methanopyrrolidine based scaffold.

CYCLOPROPYL-FUSED PYRROLIDINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS

The present invention relates to DP IV-inhibitors of formula (1) for the treatment and/or prophylaxis of diseases of mammals including cancer and tumors, metastasis and tumor colonization; and metabolic diseases.